Navigation Links
Twenty New Abstracts on Oral Xeloda(R) (capecitabine) Featured at the 31st San Antonio Breast Cancer Symposium
Date:12/9/2008

ochemical staining (IHC), is associated with a clinical response of the primary tumor in women receiving neoadjuvant docetaxel-capecitabine chemotherapy for locally advanced breast cancer (Lead Author: Jeffrey Ross)

-- Dec. 14, 7:00 to 9:00 a.m., [Poster No. 6091], Survival outcome is similar for first-line chemotherapy with capecitabine or taxane for metastatic breast cancer (Lead Author: Gretchen Kimmick)

The majority of the 15 ex-U.S. abstracts being presented highlight Xeloda as a cornerstone of combination treatment. The remaining Xeloda abstract is a non-Roche sponsored study.

About XELODA (capecitabine)

Xeloda is the only FDA-approved oral chemotherapy for both metastatic breast cancer and adjuvant and metastatic colorectal cancer. Inactive in pill form, Xeloda is enzymatically activated within the body; when it comes into contact with a naturally occurring protein called thymidine phosphorylase, or TP, Xeloda is transformed into 5-FU, a cytotoxic (cell-killing) drug.

Because many cancers have higher levels of TP than does normal tissue, more 5-FU is delivered to the tumor than to other tissue.

A clinically important drug interaction between Xeloda and warfarin has been demonstrated; altered coagulation parameters and/or bleeding and death have been reported. Clinically significant increases in prothrombin time (PT) and INR have been observed within days to months after starting Xeloda, and infrequently within one month of stopping Xeloda. For patients receiving both drugs concomitantly, frequent monitoring of INR or PT is recommended. Age greater than 60 and a diagnosis of cancer independently predispose patients to an increased risk of coagulopathy.

Xeloda is contraindicated in patients who have a known hypersensitivity to 5-fluorouracil, and in patients with known dihydropyrimidine dehydrogenase (DPD) deficiency. Xeloda is contraindic
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. State Medicaid Programs to Spend $1.6 Trillion on Long-Term Care over the Next Twenty Years
2. Twenty of Americas Most Promising Scientists Selected as 2008 Pew Scholars in the Biomedical Sciences
3. MAP Pharmaceuticals to Present at the Goldman Sachs Twenty-Ninth Annual Global Healthcare Conference
4. BD to Present at the Goldman Sachs Twenty-Ninth Annual Global Healthcare Conference
5. Medco CEO to Present at the Goldman Sachs Twenty-Ninth Annual Global Healthcare Conference
6. ev3 Inc. to Present at the Goldman Sachs Twenty-Ninth Annual Global Healthcare Conference
7. Aflac Incorporated to Present at the Sanford C. Bernstein & Co., LLC Twenty-Fourth Annual Strategic Decisions Conference 2008
8. Twenty-Five Individuals Honored by Yoplait(R) for Making Extraordinary Strides in the Fight Against Breast Cancer
9. The American Liver Foundation Appoints Rick Smith, a Twenty-Year Veteran of The MS Society, as Chief Executive Officer
10. Top Twenty Health Plan Websites Named by TheRatingsGuy.com
11. Memory Pharmaceuticals Announces Six Abstracts Accepted for Presentation at Society for Neuroscience Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... of Huddersfield could help to improve the quality of ... such as butter, mayonnaise, yoghurt and fruit drinks ... for her work. , Katerina gained her MSc degree ... now she has embarked on research for a PhD. ... is investigating the potential of carbohydrates extracted from the ...
(Date:7/10/2014)... men with localized prostate cancer were more likely ... received less effective treatments and survived for shorter ... depressed, a UCLA study has found. , The ... factors such as bias against the mentally ill, ... man,s lack of investment in his general health ...
(Date:7/9/2014)... WASHINGTON, DC (July 10, 2014) If you think winning ... fun for kids think again: Winning along with other mental ... each of which falls into one of 11 big fun ... that winning is all important when it comes to the ... identify and quantify what goes into this elusive conceptuntil now. ...
(Date:7/9/2014)... at the Perelman School of Medicine at the University ... Institute have received an $8 million grant from the ... photodynamic light therapy (PDT) in patients with malignant pleural ... often manifests itself in the lining of the lungs ... The grant will fund a clinical trial and additional ...
(Date:7/9/2014)... scientific research into the metabolism of stromal support cells ... metabolism of these cell types in the development of ... inflammatory conditions and cancer. That was the conclusion of ... Leuven in the leading journal Nature . , ... of wake-up call. The metabolism of cancer cells has ...
Breaking Medicine News(10 mins):Health News:World interest in research work on the benefits of the Okra plant 2Health News:Depressed men with prostate cancer are diagnosed later stage, get less effective therapies 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 3Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Wake-up call for more research into cell metabolism 2
... Results presented today from the Atrial Fibrillation Ablation ... undergoing a catheter ablation for atrial fibrillation have ... precipitating factors are rare. The survey, which is ... programme, also confirmed that symptoms are present in ...
... team of surgeons at UT Southwestern Medical Center expects ... within a year, making the institution just the sixth ... intricate surgery. UT Southwestern received Institutional Review Board ... Transplant specialists are now screening potential patients who would ...
... MONDAY, Aug. 29 (HealthDay News) -- Hurricanes. Earthquakes. Floods. Tornadoes. ... events have left adults reeling as one disaster seems to ... relent and no apparent end in sight. Imagine, then, ... they see this stuff is everywhere," said Robin Goodman, a ...
... -- The width of a CEO,s face may predict how ... Researchers compared the photos of 55 male CEOs of Fortune ... only men because previous research found that a link between ... firms of CEOs with wider faces, relative to face height, ...
... -- Effective memory is a key ability for independent living ... is among the first to report that social partners can ... that helps middle-aged couples with memory tasks doesn,t seem to ... Margrett, an assistant professor in human development and family studies, ...
... , MONDAY, Aug. 29 (HealthDay News) -- Many ... discharged from U.S. hospitals return to the emergency department ... an outpatient clinic, a new study finds. These ... refills of pain medications. The researchers examined the ...
Cached Medicine News:Health News:The first European registry to evaluate the real-life epidemiology of atrial fibrillation ablation 2Health News:The first European registry to evaluate the real-life epidemiology of atrial fibrillation ablation 3Health News:UT Southwestern launches hand transplant program 2Health News:For Kids, Natural Disasters Can Whip Up Worries 2Health News:For Kids, Natural Disasters Can Whip Up Worries 3Health News:Study examines how couples' collaborative dialogue may assist in a spouse's memory 2Health News:Study examines how couples' collaborative dialogue may assist in a spouse's memory 3Health News:Many Use ER for Routine Follow-Up Care After Hospital Discharge 2
(Date:1/15/2014)... to Millennium Research Group (MRG), the global authority ... United States and European transcatheter embolization ... through 2022, with embolization particles representing one of ... drug-eluting beads (DEBs) and radioembolization spheres in interventional ...
(Date:1/15/2014)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") ... its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for ... Solta Medical, Inc. (NASDAQ: SLTM ) ("Solta") ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a leading ... of severely obese patients, today announced initial results ... selective inhibitor of methionine aminopeptidase 2 (MetAP2), in ... of genetic obesity.  These results showed improvements in ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... England, July 29, 2011 , ... The UK bioindustry has raised over $250m in financing ... any quarter for one year, and the second largest amount raised ... to the financing drought that saw three consecutive quarters below $100m ...
... Health Company (Nasdaq: FHCO ) today announced that ... operating results for the third quarter and first nine months ... Eastern Time (EDT).  The Company expects to report its operating ... other interested parties may participate in the conference call by ...
Cached Medicine Technology:UK Chalks Up $253 Million in Investment in Q2 2011: Oxford Cluster Takes the Largest Bite of the Apple 2UK Chalks Up $253 Million in Investment in Q2 2011: Oxford Cluster Takes the Largest Bite of the Apple 3The Female Health Company to Host Third Quarter Conference Call on Friday, August 5, 2011 2
... for the mid- to high-volume lab, the ... can reduce time-consuming manual tasks by as ... performs random access, STAT, HCFA panels and ... including Stat chemistries, General chemistries, TDMs, DATs, ...
... It takes powerful technology to ... safety, and still lower costs. ... LX20 PRO, offering features that ... any other chemistry analyzer, including ...
... This user-friendly instrument ... Plasma Protein analyzer for ... It is a well ... reliable results for a ...
For Detection of Bile Component in Reflux Disease...
Medicine Products: